Abstract

RationaleDopamine stabilizers have stimulatory actions under low dopamine tone and inhibitory actions under high dopamine tone without eliciting catalepsy. These compounds are dopamine D2 receptor (D2R) antagonists or weak partial agonists and may have pro-mnemonic and neuroprotective effects. The mechanism underlying their stimulatory and neuroprotective actions is unknown but could involve sigma-1R binding.ObjectivesThe present study examined sigma-1R and D2R occupancy by the dopamine stabilizer pridopidine (ACR16) at behaviorally relevant doses in living rats.MethodsRats were administered 3 or 15 mg/kg pridopidine, or saline, before injection of the radiotracer 11C-SA4503 (sigma-1R) or 11C-raclopride (D2R). Some animals received 60 mg/kg pridopidine and were only scanned with 11C-raclopride. Cerebral 11C-SA4503 binding was quantified using metabolite-corrected plasma input data and distribution volume (VT) calculated by Logan graphical analysis. 11C-raclopride binding was quantified using striatum-to-cerebellum ratios and binding potentials calculated with a simplified reference tissue model.ResultsCunningham-Lassen plots indicated sigma-1R occupancies of 57 ± 2 and 85 ± 2 % after pretreatment of animals with 3 and 15 mg/kg pridopidine. A significant (44–66 %) reduction of 11C-raclopride binding was only observed at 60 mg/kg pridopidine.ConclusionsAt doses shown to elicit neurochemical and behavioral effects, pridopidine occupied a large fraction of sigma-1Rs and a negligible fraction of D2Rs. Significant D2R occupancy was only observed at a dose 20-fold higher than was required for sigma-1R occupancy. The characteristics of dopamine stabilizers may result from the combination of high sigma-1R and low D2R affinity.

Highlights

  • Pridopidine is a phenylpiperidine compound undergoing clinical trials for treatment of motor symptoms in Huntington’s disease

  • Significant D2 receptor (D2R) occupancy was only observed at a dose 20-fold higher than was required for sigma-1R occupancy

  • The characteristics of dopamine stabilizers may result from the combination of high sigma-1R and low D2R affinity

Read more

Summary

Introduction

Pridopidine ( known as ACR16 or Huntexil) is a phenylpiperidine compound undergoing clinical trials for treatment of motor symptoms in Huntington’s disease (de Yebenes et al 2011; Kieburtz et al 2013; for the ongoing Pride-HD trial, see NCT02006472 at clinicaltrials.gov). Pridopidine stimulates locomotor activity in habituated animals showing low baseline locomotor activity (Rung et al 2008) and increases dopamine release in several brain regions including the prefrontal cortex (Ponten et al 2010). Based on these properties, pridopidine and structurally related compounds showing similar in vivo efficacy such as (−)-OSU6162 have been termed “dopamine stabilizers” as they exhibit inhibitory or stimulatory effects on dopamine-dependent behavior depending on the prevailing dopamine tone (Ponten et al 2010)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call